Bromo-methylfurfural

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Bromo-methylfurfural
• 英文别名: 4-bromo-3-methylfuran-2-carbaldehyde
• 化学式: C₆H₅BrO₂
• 分子量: 189.01
• InChiKey: VOPSYOPSOZGGNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
  申请人：ZHEJIANG UNIVERSITY

  公开号：US10233180B2

  公开（公告）日：2019-03-19

  Disclosed are new substituted nitrogen-containing heterocyclic derivatives represented by formula (I) as AKT inhibitors, optical isomers, pharmaceutically acceptable salts or solvates thereof, wherein the definition of R1, R2, R3, R4, R5, R6, ring A, ring C, B, Q, Y, Z and m is shown in the description for details. In addition, medicaments comprising the derivatives as active components are also disclosed, which can be useful for treating proliferative diseases, such as cancer and inflammation, especially diseases relating to AKT kinase.

  本发明公开了式(I)代表的作为AKT抑制剂的新取代含氮杂环衍生物、其光学异构体、药学上可接受的盐或溶液，其中R1、R2、R3、R4、R5、R6、环A、环C、B、Q、Y、Z和m的定义详见说明。此外，还公开了包含这些衍生物作为活性成分的药物，可用于治疗增殖性疾病，如癌症和炎症，尤其是与 AKT 激酶有关的疾病。
• SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OF ANTITUMOR THEREOF
  申请人：Zhejiang University

  公开号：EP3124486B1

  公开（公告）日：2020-12-09
• SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OFANTITUMOR THEREOF
  申请人：ZHEJIANG UNIVERSITY

  公开号：US20170107213A1

  公开（公告）日：2017-04-20

  Disclosed are new substituted nitrogen-containing heterocyclic derivatives represented by formula (I) as AKT inhibitors, optical isomers, pharmaceutically acceptable salts or solvates thereof, wherein the definition of R1, R2, R3, R4, R5, R6, ring A, ring C, B, Q, Y, Z and m is shown in the description for details. In addition, medicaments comprising the derivatives as active components are also disclosed, which can be useful for treating proliferative diseases, such as cancer and inflammation, especially diseases relating to AKT kinase.